Evidence map›Paper›PMID 42555410›Full record

ReviewHuman vaccines & immunotherapeutics2026

Comparative innate immune responses across major RNA and DNA viral infections: Mechanisms, immunopathology, and therapeutic perspectives.

Maryam Mashhadi Abolghasem Shirazi

Abstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Maryam Mashhadi Abolghasem ShiraziDepartment of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0001-6639-7221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innate immunity is the first defense against viral infections, limiting viral replication and initiating adaptive immunity. Viral pathogens are recognized by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), (RIG-I-like receptors) RLRs, and the (cyclic GMP-AMP synthase) cGAS-STING pathway, which trigger interferon production and antiviral responses. This review compares innate immune responses to major RNA viruses (influenza, SARS-CoV-2, HIV) and DNA viruses (HSV, HBV, CMV). While these viruses activate similar pathways, they differ in interferon dynamics, inflammatory responses, immune cell activation, and immune evasion mechanisms. RNA viruses often induce rapid and strong innate responses, whereas many DNA viruses establish persistence through immune modulation. Dysregulated innate immunity can contribute to cytokine storms, chronic inflammation, and tissue damage. Therapeutic strategies targeting innate immunity, such as interferons, cytokine inhibitors, PRR agonists, and host-directed antivirals, may improve outcomes. Infection severity depends on the timing, magnitude, and regulation of innate immune responses.

Indexed as

DNA VirusesDNA Virus InfectionsImmunity, InnateRNA VirusesRNA Virus InfectionsAnimalsAntiviral AgentscGAS-STING Signaling PathwayHost-Directed TherapyHumansImmune EvasionInnate Immunity RecognitionReceptors, Pattern RecognitionAntiviral AgentsReceptors, Pattern Recognitionantiviral responsesDNA virusesimmune evasionInnate immunitypattern recognition receptorsRNA virusesviral infections

Identifiers

PMID42555410
PMCPMC13449730

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.